July 31, 2014Circulation
Nationwide Study on Hypertrophic Cardiomyopathy in Iceland
Why the study?
Does the MYBPC3 c.927-2A>G mutation impact adverse event rates and cardiovascular mortality in patients with HCM in Iceland?
Population
Patients with Hypertrophic Cardiomyopathy (HCM) in Iceland
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
May inform regional HCM genetic screening; leaves open genotype-specific management strategies pending prospective validation.
Structured PICO
Does the MYBPC3 c.927-2A>G mutation impact adverse event rates and cardiovascular mortality in patients with HCM in Iceland?
P
Population
Patients with Hypertrophic Cardiomyopathy (HCM) in Iceland
I
Intervention
Presence of MYBPC3 c.927-2A>G founder mutation
O
Outcome
Adverse event rates and cardiovascular mortalityhard clinical
The MYBPC3 c.927-2A>G founder mutation in Iceland demonstrates that specific genotypes in HCM can drive distinct clinical outcomes, such as earlier cardiovascular mortality despite low overall adverse event rates.
Cite This Study
Aðalsteinsdóttir et al. (2014) studied this question.